Nitric oxide synthase expression in the splanchnic hyposensitivity to glypressin of a hemorrhage-transfused rat model with portal hypertension.
BACKGROUND
Nitric oxide (NO) has been proposed to participate in the vascular hyporesponsiveness to vasopressin and its long-acting analogue glypressin during hemorrhage in portal hypertensive states. This study surveyed the role of NO regarding splanchnic hyporeactivity to glypressin and NO synthases (NOS) expression in different vascular beds in bleeding portal-hypertensive rats.


METHODS
Under general anesthesia with ketamine, partially portal vein-ligated male Sprague-Dawley rats without or with bleeding were used to investigate the hemodynamic effects of glypressin (0.07 mg/kg intravenously) and constitutive (cNOS) and inducible NOS (iNOS) mRNA expression over the abdominal aorta and superior mesenteric artery.


RESULTS
Splanchnic hyposensitivity to glypressin was noted in the hemorrhage-transfused rats with enhanced cNOS expression of superior mesenteric artery. No significant differences of cNOS and iNOS expression in abdominal aorta and iNOS in superior mesenteric artery were found between the with-bleeding and without-bleeding groups.


CONCLUSIONS
In rats with portal hypertension and acute hemorrhage, cNOS over-expression in superior mesenteric artery may take a part in the splanchnic hyposensitivity to glypressin.
Huang
Hui-Chun
HC
Divisions of Gastroenterology National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC.
Chen
Yi-Chou
YC
Wang
Sun-Sang
SS
Chan
Che-Chang
CC
Lee
Fa-Yauh
FY
Chang
Full-Young
FY
Lin
Han-Chieh
HC
Hou
Ming-Chih
MC
Lu
Rei-Hwa
RH
Wu
Shwu-Ling
SL
Lee
Shou-Dong
SD
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006470:Hemorrhage / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D006975:Hypertension, Portal / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D008236:Lypressin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000235:genetics* / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077585:Terlipressin
D000959:Antihypertensive Agents; D012333:RNA, Messenger; D008236:Lypressin; D000077585:Terlipressin; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496318:Nos2 protein, rat; C496316:Nos3 protein, rat